🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

An International Health Concern

Cases of gonorrhoea are escalating globally, with estimates suggesting more than 82 million instances each year. Notably increased rates are reported in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the context of rising global incidence, escalating drug resistance and the very limited available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to major issues, including infertility. Scientists hope that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per findings detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which involves an injection and a pill. The trial enrolled hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Medical professionals on the front lines have voiced optimism. Access to a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for public health efforts. This is deemed vital to lessen the impact of the illness for patients and to prevent the spread of extremely resistant gonorrhoea globally.